Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 2, 2011, Pages 177-183

  Devitt, Emma J ^a   Power, Karen A ^b   Lawless, Matthew W ^a   Browne, John A ^a   Gaora, Peadar Ó ^b   Gallagher, William M ^b   Crowe, John ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

early viral response; hepatitis C; protein chip; proteomics; random forest; surface enhanced laser desorption ionization

Indexed keywords

BIOLOGICAL MARKER; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ACCURACY; ADULT; ANTIVIRAL THERAPY; ARTICLE; BIOCHIP; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PROTEOMICS; RECOMBINANT PROTEINS; RIBAVIRIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79851514364     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283424e3e     Document Type: Article

References (35)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47.
2. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34(4Pt 1):809-816. (Pubitemid 32928008)
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1):S35-S46. (Pubitemid 35253462)
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med2004; 140:346-355.
7. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425:905.
8. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40kd)/ribavirin therapy. Hepatology2006; 43:954-960. (Pubitemid 43724620)
9. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2or3.N Engl J Med 2005; 352:2609-2617. (Pubitemid 41007847)
10. Pearlman BL. Chronic hepatitis Ctherapy: changing the rules of duration. Clin Gastroenterol Hepatol 2006; 4:963-971. (Pubitemid 44118848)
11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
12. Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, et al. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 2007; 45:948-956. (Pubitemid 46631563)
13. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006; 6:2865-2873.
14. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005; 41: 40-47. (Pubitemid 40066381)
15. Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer2006; 94:287-292. (Pubitemid 43151549)
16. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14:470-477. (Pubitemid 351226115)
17. Paradis V, Asselah T, Dargere D, Ripault MP, Martinot M, Boyer N, et al. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology2006; 130:2189-2197. (Pubitemid 43816965)
18. Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther2007; 26:847-858. (Pubitemid 47346704)
19. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41:634-642. (Pubitemid 40289513)
20. Kiehntopf M, Siegmund R, Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 2007; 45:1435-1449. (Pubitemid 350036581)
21. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM. Applications of SELDI-MS technology in oncology. J Cell Mol Med 2008; 12:1535-1547.
22. Breiman L. Random forests. Machine Learning 2001; 45:5-32. (Pubitemid 32933532)
23. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
24. RDevelopmentCoreTeam R: A language and environment for statistical computing. 2008: R Foundation for Statistical Computing, Vienna, Austria.
25. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3. Article3.
26. Diboun I, Wernisch L, Orengo CA, Koltzenburg M. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using LIMMA. BMC Genomics 2006; 7:252.
27. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, Kjellman M, et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005; 138: 1087-1094. (Pubitemid 41797349)
28. Beyer S, Walter Y, Hellmann J, Kramer PJ, Kopp-Schneider A, Kroeger M, Ittrich C. Comparison of software tools to improve the detection of carcinogen induced changes in the rat liver proteome by analyzing SELDI-TOF-MS spectra. J Proteome Res 2006; 5:254-261. (Pubitemid 43222293)
29. Liaw A. Classification and Regression by randomforest. R News 2002; 2:18-22.
30. Granitto PM. Recursive feature elimination with random forest for PTR-MS analysis of agroindustrial products. Chemom Intell Lab Syst 2006; 83:83-90. (Pubitemid 44331978)
31. Diaz-Uriarte R, Alvarez de Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006; 7:3.
32. Whistler T, Rollin D, Vernon SD. A method for improving SELDI-TOF mass spectrometry data quality. Proteome Sci 2007; 5:14.
33. Rollin D, Whistler T, Vernon SD. Laboratory methods to improve SELDI peak detection and quantitation. Proteome Sci 2007; 5:9.
34. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, Selby PJ. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005; 51:1637-1649. (Pubitemid 41233099)
35. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis c infection: the future of personalized HCV therapies. Am J Gastroenterol 2010. [Epub ahead of print]